SEC Filings

AVEXIS, INC. filed this Form 424B5 on 06/19/2017
Entire Document

Use these links to rapidly review the document

Table of Contents

Filed Pursuant to Rule 424(b)(5)
Registration No. 333-216814

This information in this preliminary prospectus supplement is not complete and may be changed. A registration statement relating to these securities has been filed with the Securities and Exchange Commission and is effective. This preliminary prospectus supplement and the accompanying prospectus are not an offer to sell the securities and we are not soliciting an offer to buy these securities in any jurisdiction where the offer or sale is not permitted.

Subject to Completion, dated June 19, 2017

(To the Prospectus dated March 17, 2017)



Common Stock

          We are offering up to $200,000,000 of shares of our common stock pursuant to this prospectus supplement and the accompanying prospectus.

          Our common stock is listed on The NASDAQ Global Select Market under the symbol "AVXS." The last reported sale price of our common stock on The NASDAQ Global Select Market on June 16, 2017 was $70.88 per share.

          We are an "emerging growth company" as that term is used in the Jumpstart Our Business Startups Act of 2012 and, as such, have elected to comply with certain reduced public company reporting requirements.

          Investing in our common stock involves a high degree of risk. See "Risk Factors," beginning on page S-6 of this prospectus supplement, as well as in the documents incorporated or deemed to be incorporated by reference into this prospectus supplement, for a discussion of the factors you should carefully consider before deciding to purchase our common stock.

          Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus supplement or the accompanying prospectus. Any representation to the contrary is a criminal offense.

  Per Share   Total

Public offering price

  $   $  

Underwriting discounts and commissions(1)

  $   $  

Proceeds to AveXis, Inc., before expenses

  $   $  

See "Underwriting" beginning on page S-24 for additional information regarding underwriting compensation.

          We intend to offer the underwriters the option to purchase up to an additional $30,000,000 in shares of our common stock from us at the initial price to the public less the estimated underwriting discount and commission, within 30 days from the date of this prospectus supplement.

          The underwriters expect to deliver the shares against payment in New York, New York on or about                          , 2017.

Goldman Sachs & Co. LLC   Jefferies   BofA Merrill Lynch



BMO Capital Markets



Prospectus supplement dated June     , 2017

© AveXis, Inc. All Rights Reserved.